"We are convinced that #academic CAR T-cell therapy will play an increasingly important role in cancer therapeutics... It would be unfair to leave our patients to their own devices when there is so much we can do for them" In Focus #CARtx Hospital Clínic thelancet.com/journals/lanha…

Outcomes of acute myeloid leukemia patients who responded to venetoclax and azacitidine and stopped treatment Open access: doi.org/10.1002/ajh.27… #LeuSM #AML

Clinical outcomes of hypomethylating agents and venetoclax in newly diagnosed unfit and relapsed/refractory paediatric, adolescent and young adult acute myeloid leukaemia patients buff.ly/4d1Umqo

This is happening…

Full article available right now at Annals of Hematology! Clinical management of patients diagnosed with acute myeloid leukemia treated with venetoclax in combination with hypomethylating agents after achieving a response: a real-life study link.springer.com/article/10.100…

🎉 Enhorabuena a la Dra Queralt Salas y al resto de investigadores del grupo de trabajo de Complicaciones No Infecciosas del GETH por su reciente publicación abordando los retos del manejo de los efectos adversos cardíacos tras #TPH con #PTCy 👉 ashpublications.org/bloodadvances/…

Our study on UBA1 mutations in MDS is out this week in Blood!

Data-driven, harmonised classification system for MDS sciencedirect.com/science/articl… It took a global effort for this project using largest MDS cohort to date from Moffitt and Genomed datasets. Thx to all my dear coauthors Moffitt Cancer Center Amer Zeidan MBBS,MHS ‏عامر زيدان Somedeb Ball GenoMed4All International Consortium for MDS (icMDS)

Happy to share our report on the utility of post remission use of GCSF in the VIALE-A trial. In the CR/CRi patients given GCSF, OS was 30.8 m vs 21.1 mo and MRD neg response 51% vs 33%. Important data to feel safe to use GCSF w/ blast clearance. onlinelibrary.wiley.com/doi/10.1002/aj…

nature.com/articles/s4137… We summarized the evidence on MRD in AML & its role in clinical practice: when & how to use it for guiding therapeutic decisions. 🙏 for my co-authors Amer Zeidan MBBS,MHS ‏عامر زيدان Sanam Loghavi, MD صنم لغوی 🔬🧬 Anthony Perissinotti, & Chris Hourigan for his valuable review Leukemia Journal

Our latest work is out in Molecular Therapy! We present ARI0003, dual-targeting CD19/BCMA CAR-T cells for lymphoma. We performed an exhaustive characterization of strategies to generate dual CAR-T cells. This CAR-T therapy is now under clinical investigation. ➡️ cell.com/molecular-ther…

CONGRESS | #ASH24 | PRESENTATION Carlos Jimenez-Vicente Carlos Jiménez-Vicente Hospital Clínic Hematologia Hospital Clínic Barcelona presents results from a retrospective analysis that assessed the allo-HSCT refined ELN risk classification, with the new very poor risk group (adverse-plus), in patients with

Really happy to have presented ASH 2024 two oral presentations on behalf of the GETH and CETLAM about the AlloHCT Refined ELN 2022 Risk Classification validation and the prognostic value of MRD in AML patients treated with VenHMA Hematologia Hospital Clínic Barcelona

Carlos Jimenez Carlos Jiménez-Vicente from Hematologia Hospital Clínic Barcelona presented at #ASH2024 a collaborative study by CETLAM highlighting the prognostic role of MRD assessment in AML patients treated with VEN+HMA

New 📄🚨on everyone's least favorite myeloid neoplasms:TP53m AML&MDS 🧵In short: 🔴pls don’t exclude these pts of allo-HSCT, their only chance at cure.   🔴TP53 burden is key 🔴Blasts matter (for real… not only b/c I’m a pathologist 🔬😉) haematologica.org/article/view/1…

Thrilled to share our latest study: “At-Home (AH) care program for Acute Myeloid Leukemia (AML) patients undergoing induction therapy with Venetoclax + Azacitidine (VenAza) 🧵 mdpi.com/3100452 #mdpicancers via Cancers MDPI

Excited to share my VJHemOnc interviews from #ASH24! Validation of MRD prognostic value in AML treated with VenHMA and the HCT-Refined ELN 2022 for AML allografted patients Thanks to ASH & VJHemOnc! Watch here 👉: youtube.com/watch?v=7T6Ctp… youtube.com/watch?v=8XqTDv…

Just published🎉 Real-life outcomes of 1034 AML patients treated with intensive chemotherapy within CETLAM AML-12 protocol: nature.com/articles/s4140…

Excited to share our latest study in Blood Cancer Journal! We’ve validated the AlloHCT-refined #ELN2022 risk classification for AML patients undergoing AlloHCT spotlighting the high‐risk Adv-Plus group Thanks to all authors from GETH for their help. nature.com/articles/s4140…

Our 6-center Spanish CETLAM study of 99 AML pts on VenHMA achieving a morphological response is out in Blood Cancer Journal. Achieving MRD– improved OS (23.3 vs 15.2m, p=0.006) and LFS being the only independent factor in MVA. Thanks to all authors! nature.com/articles/s4140…